As semaglutide enters its off-patent phase in multiple markets, the implications extend well beyond pricing. This analysis examines how regulatory interpretation, access dynamics and competitive responses may reshape the metabolic landscape. Read the blog for strategic insights. https://lnkd.in/d2k9f2eN
IQVIA Commercial Solutions: Global Market Insights
Pharmaceutical Manufacturing
Durham, North Carolina 23,006 followers
About us
Through our Gold Standard data and analytics, Global Market Insights supports pharmaceutical and life sciences organizations in measuring, managing and segmenting markets, finding and sizing opportunities and maximizing the return on investment across the pharmaceutical drug lifecycle worldwide.
- Website
-
https://www.iqvia.com
External link for IQVIA Commercial Solutions: Global Market Insights
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
Updates
-
Pipeline intelligence, 10-year forecasts, and protection insights—now in minutes. Compiling competitor pipelines and launch timelines across markets used to take weeks. Now, IQVIA Global Market Insights (GMI) Agent delivers the full picture in one question—powered by agentic AI and IQVIA’s gold-standard data for smarter, faster decisions across 95% of the global market. Swipe to see how it works. Explore the new IQVIA GMI Agent. https://lnkd.in/escT8q47
-
Pharma deal activity fell 12% in 2025, yet deal value surged as companies made fewer, higher‑impact bets — including nine acquisitions over US$10B. Find out what’s driving this focus on quality, how licensing and R&D strategies are evolving, and what it means for dealmaking in the 2025 Pharma Deals Annual Review. Download the Pharma Deals white paper now: https://lnkd.in/eQH8gMBA
-
Obesity is entering a commercial inflection point. In our latest blog, we explore what’s changing as oral GLP‑1s launch, semaglutide moves off‑patent across major markets, and access and affordability begin to expand — all while competition accelerates. Read the IQVIA Early Bird: 2025 Revealed – The Trends Shaping Pharma’s Future blog for trends shaping obesity, oncology, immunology and global pharma growth heading into 2026. https://lnkd.in/eUBFQVs5
-
-
Global Market Insights (GMI) Agent just levelled up. GMI Agent now provides brand-level forecasting, pipeline visibility, and patent & exclusivity insights. Connected to HCP sentiment, competitive intelligence, sales trends, and channel performance benchmarks, it delivers clear guidance on where to focus and how to adapt strategies for stronger results. Experience faster answers, smarter decisions, and maximum outcomes across the entire product lifecycle—powered by agentic AI and IQVIA’s gold-standard data sources. Answers in minutes instead of weeks. Explore the new GMI Agent. https://lnkd.in/euk77e_C
-
Missed the live webinar? IQVIA Early Bird: 2025 Revealed – The Trends Shaping Pharma’s Future brings together the data behind the forces reshaping commercial strategy in 2026 — from loss of exclusivity and accelerated innovation, to diverging market performance across key therapy areas. Watch the on-demand webinar for a clear, data-driven view of what’s changing across obesity, oncology and immunology — and why it matters. https://lnkd.in/egjzuvJm
-
-
Growth is accelerating in pharma — but it’s increasingly concentrated. In our latest blog, IQVIA Early Bird: 2025 Revealed – The Trends Shaping Pharma’s Future, we examine how 2025 reshaped the industry, from regional concentration and a more complex launch environment to novel modality‑driven oncology growth and obesity’s rapid rise as a global value driver. Against rising loss‑of‑exclusivity pressure, these shifts are redefining where growth comes from and how sustainable it really is. Read the blog for an early view of the market, therapy‑area and commercialization trends shaping pharma in 2026. https://lnkd.in/enMUV58P
-
-
NEW WHITEPAPER: Deal volumes fell in 2025, but pharma focused investment on fewer, higher‑confidence assets, driving a 99% increase in M&A spend — understand what’s really driving dealmaking, valuations, and priorities in the 2025 Pharma Deals Annual Review. Download the white paper: https://lnkd.in/efFqG9JQ
-
-
Pre‑testing HCP engagement before investing is emerging as a smarter way to plan commercial strategy. In PharmaLive's Agenda 2026 series, Kapil Chaddha, Director of New Product Development at IQVIA, shares how HCP Digital Twins enable teams to simulate campaign response early — supporting faster, more precise decision‑making. Read the full article here: https://lnkd.in/ex3vs7Hi
-
-
The on-demand IQVIA Early Bird webinar provides a clear, data-driven breakdown of 2025 global market trends — from sales value and volume dynamics to therapy area evolution, promotional mix, and launch performance, to help you understand the numbers behind what is changing and why. Watch the webinar on-demand for a strategic perspective to support confident commercial decision-making in the year ahead: https://lnkd.in/eGT63n-g
-